Table 1.
Patient characteristics
| LDMC | CCT | p | |||
|---|---|---|---|---|---|
| n = 40 | n = 80 | ||||
| Median age at start of therapy (range) (years) | 63 (35–83) | 61 (30–81) | 0.230 | ||
| Median age at FD MBC (range) (years) | 59 (33–82) | 59 (28–81) | 0.544 | ||
| Median age at FD BC (range) (years) | 51 (29–80) | 52 (26–79) | 0.506 | ||
| Age at start of therapy | |||||
| Younger | 20 (50.0%) | 40 (50.0%) | 1.000 | ||
| Elderly | 20 (50.0%) | 40 (50.0%) | |||
| Chemotherapy line | |||||
| Non-heavily pretreated | 21 (52.5%) | 42 (52.5%) | 1.000 | ||
| Heavily pretreated | 19 (47.5%) | 38 (47.5%) | |||
| Metastatic sites | |||||
| No multiple metastases | 25 (62.5%) | 50 (62.5%) | 1.000 | ||
| Multiple metastases | 15 (37.5%) | 30 (37.5%) | |||
| HR status | |||||
| HR-positive | 30 (75.0%) | 60 (75.0%) | 1.000 | ||
| Triple-negative | 10 (25.0%) | 20 (25.0%) | |||
LDMC low-dose metronomic chemotherapy, CCT conventional chemotherapy, FD first diagnosis, MBC metastatic breast cancer, BC breast cancer, HR hormone receptor